None listed
Conditions
Brief summary
This is a prospective observational exploratory study investigating the immunological effects of RSV vaccination in pregnant women. All pregnant women will receive a single dose of the Abrysvo RSV vaccine. Detailed exploratory systems biology assays (transcriptomics, epigenetics, lipidomics, metabolomics) and flow cytometry will be performed to investigate the broad immunomodulatory effects of RSV vaccination.
Interventions
A single 0.5 mL dose of Abrysvo RSV vaccine administered by intramuscular injection from 28 weeks' gestation. This vaccine is offered to all pregnant women whether they participate in the trial or not, but we will recruit those who agree to vaccination and wish to participate in the trial.
Sponsors
Tasmanian Health Service
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Pregnant. Aged 18 years and above. Healthy uncomplicated pregnancy at 28 weeks' gestation or more. Ability to communicate in English. Ability to communicate by mobile telephone and text messaging.
Exclusion criteria
<18 years old. Less that 28 weeks' gestation. Inability to speak and/or understand English. Inability to provide informed consent. Known allergy or contraindication to Abrysvo RSV vaccination. Unwilling to give consent to participate. Unlikely to be available for the duration of the study.
Outcome results
None listed